Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer.
about
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerIntra-tumor heterogeneity of cancer cells and its implications for cancer treatmentTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesHigh efficiency vortex trapping of circulating tumor cells.Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer.Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysisTumour heterogeneity in the clinic.Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?Prevalence and clinical significance of BRAF V600E in Chinese patients with lung adenocarcinoma.Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutationsA sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor.Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases.High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma.The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations.Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-small cell lung cancer cellsExploring the impact of EGFR T790M neighboring SNPs on ARMS-based T790M mutation assayComprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology.Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.Emerging protein kinase inhibitors for non-small cell lung cancer.EGFR mutations in lung cancer: from tissue testing to liquid biopsy.Current and future molecular diagnostics in non-small-cell lung cancer.Spatial distribution of EGFR and KRAS mutation frequencies correlates with histological growth patterns of lung adenocarcinomas.Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas.SinCHet: a MATLAB toolbox for single cell heterogeneity analysis in cancer.Impact of Cell-surface Antigen Expression on Target Engagement and Function of an Epidermal Growth Factor Receptor × c-MET Bispecific Antibody.EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistanceThe detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.Three-Dimensional Patient-Derived In Vitro Sarcoma Models: Promising Tools for Improving Clinical Tumor Management.Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases.Tumour heterogeneity and resistance to cancer therapies.Discrepancy of epidermal growth factor receptor mutation in lung adenocarcinoma presenting as multiple ground-glass opacities.Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.Multiregion sequencing reveals the intratumor heterogeneity of driver mutations in TP53-driven non-small cell lung cancer.Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?Anastomotic recurrence of colon cancer: Genetic analysis challenges the widely held theories of cancerous cells' intraluminal implantation and metachronous carcinogenesis.[Diagnosis and Treatment for Multiple Primary Lung Cancer].
P2860
Q26471909-CFD9DCA8-264C-4340-862F-D7565D36A1D0Q26783055-7030F9D9-FC25-4F55-9B42-65C69831CBD8Q27014117-690AB4FA-1D5B-4D60-8AB5-ADE43656B310Q30367788-9D731092-F6E3-485C-89D6-C5D3F229E88AQ33598423-3ED5BFD3-3D89-407B-925C-134B1E45FB7FQ33700689-76615477-9C9A-4A9B-922E-A1BA42495A0EQ34258399-4F2DC088-EB44-45A3-AFED-508AE0F60737Q34372080-887A1D27-B1E3-41EB-BE41-E696B4D316A2Q35537522-7D13B91D-E0C2-492D-AFAC-DA2E9C7E78B0Q35663416-17E9AF07-67B7-4359-935F-18A581DCF3DCQ36477762-A91CF4DA-5FB9-4F7D-9DCE-99386926075FQ36742126-C813CA6D-12C8-446B-B3C4-48A0DE390594Q36924440-031BA820-8568-4034-B2CE-964F740040EAQ36948934-10A89775-F327-4A18-B224-D801FA4CE770Q37077933-5B9109AB-AD53-48CF-96A3-4252037BD172Q37190448-33C5E65A-9AC3-4786-9A3A-3066559CE791Q37269183-94151315-B169-42A2-B6D3-1D271F091907Q37407368-5FD0F6E4-38B7-4CE0-95A9-E91FFF0927A9Q37580410-2B9CD381-D4EE-4DD0-908F-7FD7F352F64FQ37665697-6CA57693-E29B-4679-93B4-428452E9871EQ38172608-96875DAB-A3BD-4FAA-BF42-AA7CA90A52ACQ38515822-A47AAD97-6633-4DB9-A8D2-930712710EE5Q38543780-4E021953-98C1-4F8A-B0D8-2A49935055C7Q38683041-8B1B6846-83E0-4AAF-B093-255A0C715DF3Q38790179-88CA8C62-6D8A-4858-B112-A5991282C316Q38804066-5566D9B5-332B-4423-AD03-523108071F25Q38844694-C4A56188-A11F-4D53-98E5-6B2B2B242412Q41166613-A40A7670-D05D-4BD1-BA17-95F102CDBB9BQ41472736-C57078D8-86C4-46F8-B807-B07AFEBBD942Q41684395-5D1F08A0-4D39-404C-B4ED-F99693721D69Q42835050-C921337B-344F-4052-A9C4-D2A40785B57CQ46505392-AE734A52-2EA7-4F24-A26E-8E665893B57CQ48889821-458AC1A4-770D-4B6F-AA01-6FCCE9C3D768Q50112440-CE2D8408-5C84-4B15-8A39-785F09FFE0D3Q50865313-C307AEA0-0D3C-47B4-9D56-EB7B77A6D977Q51034792-F72B0A2B-3323-4D98-BA25-C37E8E7CC8D2Q51453469-73BC921D-22A1-46B7-86AC-078D80BCB2B4Q53060849-829901AB-4660-4768-8380-6681E4980343Q53105640-7F914DC8-9EC6-4714-B6C5-05126FAA7D73Q55496646-D06D7DEB-8081-41C7-828F-1E38E2424A42
P2860
Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Detection and clinical signifi ...... ed non-small cell lung cancer.
@ast
Detection and clinical signifi ...... ed non-small cell lung cancer.
@en
Detection and clinical signifi ...... ed non-small cell lung cancer.
@nl
type
label
Detection and clinical signifi ...... ed non-small cell lung cancer.
@ast
Detection and clinical signifi ...... ed non-small cell lung cancer.
@en
Detection and clinical signifi ...... ed non-small cell lung cancer.
@nl
prefLabel
Detection and clinical signifi ...... ed non-small cell lung cancer.
@ast
Detection and clinical signifi ...... ed non-small cell lung cancer.
@en
Detection and clinical signifi ...... ed non-small cell lung cancer.
@nl
P2093
P2860
P1433
P1476
Detection and clinical signifi ...... ced non-small cell lung cancer
@en
P2093
Jianchun Duan
Qinghua Zhou
Tongtong An
Yuyan Wang
Zhijie Wang
P2860
P304
P356
10.1371/JOURNAL.PONE.0054170
P407
P50
P577
2013-02-13T00:00:00Z